Waleed T. Kayani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Waleed T. Kayani has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Hani Jneid
Department of Cardiovascular Medicine, University of Texas Medical Branch, Galveston, Texas
6 shared publications - Mahboob Alam
The Texas Heart Institute, Baylor College of Medicine, Houston, TX 77030, USA
6 shared publications Hani Jneid
Baylor College of Medicine, Houston, Texas
4 shared publications- Salim Shahbuddin Virani
Aga Khan University
4 shared publications - Mahin R. Khan
Division of Cardiology, McLaren-Flint/Michigan State University, Flint, MI, USA
3 shared publications - Xiaoming Jia
Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, USA
3 shared publications
Latest Publications
- 13 December 2025
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 40 (4) , 1-9
Association between Oral Beta Blocker Therapy and long-term Outcomes after Myocardial Infarction in Individuals with Mildly Reduced or Preserved Left Ventricular Function – a Meta-Analysis of Contemporary Randomized Controlled Trials
Background In the contemporary reperfusion era, the benefit of beta-blocker therapy in patients after acute myocardial infarction (AMI) and preserved left ventricular ejection fraction (LVEF ≥50%) remains unclear. Recently conducted clinical trials have demonstrated mixed results about the clinical benefit of beta-blockers after myocardial infarction in pooled populations of patients with mildly reduced (LVEF 40–49%) or preserved LVEF. However, new evidence suggests a consistent benefit of beta-blocker therapy in patients specifically with mildly reduced LVEF. We aimed to assess the efficacy of beta-blockers in patients with recent myocardial infarction and mildly reduced or preserved LVEF, as well as specifically with preserved LVEF. Methods We conducted a systematic review of recent randomized controlled trials that evaluated the effects of oral beta-blocker therapy in patients with AMI who had either mildly reduced LVEF or preserved LVEF and with follow-up data of at least 1 year. Using a Mantel-Haenszel random effects model, we computed risk ratios (RR) with 95% confidence intervals for the primary composite outcome along with individual outcomes of death, re-infarction, and heart failure between patients with and without beta-blocker therapy. We performed analysis of the pooled overall study population, which included patients with mildly reduced LVEF and preserved LVEF, as well as performed subgroup analysis of patients with preserved versus mildly reduced LVEF and among men versus women. Results 19,826 patients with mildly reduced or preserved LVEF were included in the meta-analysis. Overall, 9,892 patients were assigned to beta-blockers and 9,934 to no beta-blockers. Among the pooled population, we did not demonstrate significant differences between the beta-blocker group and the control group for the primary composite outcome (RR 0.93, 95% CI 0.83–1.04), all-cause death, reinfarction, or heart failure. We further did not detect differences in the primary outcome by sex. While there was no differences in the primary composite outcome among patients with preserved LVEF (RR 0.96, 95% CI 0.86–1.08), there was reduction in risk observed among individuals with mildly reduced LVEF (RR 0.76, 95% CI 0.61–0.94). Conclusion Oral beta-blocker therapy was not associated with a reduction in the primary composite outcome in patients with preserved LVEF. This contrasts with their established benefit in patients with reduced LVEF and the growing evidence of benefit in those with mildly reduced LVEF.
- 13 December 2025
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 40 (4) , 1-9
Association between Oral Beta Blocker Therapy and long-term Outcomes after Myocardial Infarction in Individuals with Mildly Reduced or Preserved Left Ventricular Function – a Meta-Analysis of Contemporary Randomized Controlled Trials
Background In the contemporary reperfusion era, the benefit of beta-blocker therapy in patients after acute myocardial infarction (AMI) and preserved left ventricular ejection fraction (LVEF ≥50%) remains unclear. Recently conducted clinical trials have demonstrated mixed results about the clinical benefit of beta-blockers after myocardial infarction in pooled populations of patients with mildly reduced (LVEF 40–49%) or preserved LVEF. However, new evidence suggests a consistent benefit of beta-blocker therapy in patients specifically with mildly reduced LVEF. We aimed to assess the efficacy of beta-blockers in patients with recent myocardial infarction and mildly reduced or preserved LVEF, as well as specifically with preserved LVEF. Methods We conducted a systematic review of recent randomized controlled trials that evaluated the effects of oral beta-blocker therapy in patients with AMI who had either mildly reduced LVEF or preserved LVEF and with follow-up data of at least 1 year. Using a Mantel-Haenszel random effects model, we computed risk ratios (RR) with 95% confidence intervals for the primary composite outcome along with individual outcomes of death, re-infarction, and heart failure between patients with and without beta-blocker therapy. We performed analysis of the pooled overall study population, which included patients with mildly reduced LVEF and preserved LVEF, as well as performed subgroup analysis of patients with preserved versus mildly reduced LVEF and among men versus women. Results 19,826 patients with mildly reduced or preserved LVEF were included in the meta-analysis. Overall, 9,892 patients were assigned to beta-blockers and 9,934 to no beta-blockers. Among the pooled population, we did not demonstrate significant differences between the beta-blocker group and the control group for the primary composite outcome (RR 0.93, 95% CI 0.83–1.04), all-cause death, reinfarction, or heart failure. We further did not detect differences in the primary outcome by sex. While there was no differences in the primary composite outcome among patients with preserved LVEF (RR 0.96, 95% CI 0.86–1.08), there was reduction in risk observed among individuals with mildly reduced LVEF (RR 0.76, 95% CI 0.61–0.94). Conclusion Oral beta-blocker therapy was not associated with a reduction in the primary composite outcome in patients with preserved LVEF. This contrasts with their established benefit in patients with reduced LVEF and the growing evidence of benefit in those with mildly reduced LVEF.
- Open Access
- 10 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (14) , 4906
Innovations in TAVR: The Latest in Device Technology
Aortic stenosis is the most prevalent valvular disease globally. Transcatheter aortic valve replacement (TAVR) has become a well-established treatment for aortic stenosis, offering outcomes comparable to surgical aortic valve replacement (SAVR). Its use has expanded to include younger, lower-risk patients and those with more complex anatomies. Recent advancements in TAVR include the increased adoption of transfemoral access, prosthesis designs optimized for challenging anatomies, enhanced delivery systems with repositioning capabilities, and outer skirts to minimize paravalvular leaks. Despite these innovations, several challenges remain. This review highlights recent updates in transcatheter heart valve (THV) systems, leaflet modification devices, and the current limitations of TAVR.
- 10 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (14) , 4906
Open AccessInnovations in TAVR: The Latest in Device Technology
Aortic stenosis is the most prevalent valvular disease globally. Transcatheter aortic valve replacement (TAVR) has become a well-established treatment for aortic stenosis, offering outcomes comparable to surgical aortic valve replacement (SAVR). Its use has expanded to include younger, lower-risk patients and those with more complex anatomies. Recent advancements in TAVR include the increased adoption of transfemoral access, prosthesis designs optimized for challenging anatomies, enhanced delivery systems with repositioning capabilities, and outer skirts to minimize paravalvular leaks. Despite these innovations, several challenges remain. This review highlights recent updates in transcatheter heart valve (THV) systems, leaflet modification devices, and the current limitations of TAVR.
- Open Access
- 20 May 2024
- Published by Houston Methodist DeBakey Heart & Vascular Center in Methodist DeBakey Cardiovascular Journal
- Vol. 20 (1) , 26-32
The Great Masquerade: Not All Coronary Artery Stenosis Are Created Equal
We present the case of a 60-year-old male, with active smoking and cocaine use disorder, who reported progressive chest pain. Various anatomical and functional cardiac imaging, performed to further evaluate chest pain etiology, revealed changing severity and distribution of left main artery (LMA) stenosis, raising suspicion for vasospasm. Intracoronary nitroglycerin relieved the vasospasm, with resolution of the LMA pseudostenosis. A diagnosis of vasospastic angina (VA) led to starting appropriate medical therapy with lifestyle modification counselling. This case highlights VA, a frequently underdiagnosed etiology of angina pectoris. We discuss when to suspect VA, its appropriate work-up, and management.
- 20 May 2024
- Published by Houston Methodist DeBakey Heart & Vascular Center in Methodist DeBakey Cardiovascular Journal
- Vol. 20 (1) , 26-32
Open AccessThe Great Masquerade: Not All Coronary Artery Stenosis Are Created Equal
We present the case of a 60-year-old male, with active smoking and cocaine use disorder, who reported progressive chest pain. Various anatomical and functional cardiac imaging, performed to further evaluate chest pain etiology, revealed changing severity and distribution of left main artery (LMA) stenosis, raising suspicion for vasospasm. Intracoronary nitroglycerin relieved the vasospasm, with resolution of the LMA pseudostenosis. A diagnosis of vasospastic angina (VA) led to starting appropriate medical therapy with lifestyle modification counselling. This case highlights VA, a frequently underdiagnosed etiology of angina pectoris. We discuss when to suspect VA, its appropriate work-up, and management.
- 7 November 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 148 (Suppl_1)
Abstract 11889: Ischemic Evaluation in Patients Presenting With Advanced Atrioventricular Block - Experience From a Large County Health System
- 7 November 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 148 (Suppl_1)
Abstract 11889: Ischemic Evaluation in Patients Presenting With Advanced Atrioventricular Block - Experience From a Large County Health System
- 13 May 2023
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 25 (6) , 267-273
Revascularization Options for Left Main Disease: What Clinicians Need to Know
Purpose of Review Left main disease represents the highest-risk lesion subset of coronary artery disease and is associated with adverse cardiovascular events. Accordingly, we aim to understand how the significance of left main disease is assessed by different modalities, followed by a review of management options in current era. Recent Findings Invasive coronary angiogram remains the gold standard for assessment of left main disease, but intracoronary imaging or physiological testing is indicated for angiographically equivocal disease. Revascularization by either coronary artery bypass surgery or percutaneous coronary intervention is strongly recommended, which have been compared by six randomized trials, as well as recent meta-analyses. Summary Surgical revascularization remains the preferred mode of revascularization, especially in patients with high lesion complexity and left ventricular dysfunction. Randomized studies are needed to understand if current-generation stents with the use of intracoronary imaging and improved medical therapy could match outcomes with surgical revascularization.
- 13 May 2023
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 25 (6) , 267-273
Revascularization Options for Left Main Disease: What Clinicians Need to Know
Purpose of Review Left main disease represents the highest-risk lesion subset of coronary artery disease and is associated with adverse cardiovascular events. Accordingly, we aim to understand how the significance of left main disease is assessed by different modalities, followed by a review of management options in current era. Recent Findings Invasive coronary angiogram remains the gold standard for assessment of left main disease, but intracoronary imaging or physiological testing is indicated for angiographically equivocal disease. Revascularization by either coronary artery bypass surgery or percutaneous coronary intervention is strongly recommended, which have been compared by six randomized trials, as well as recent meta-analyses. Summary Surgical revascularization remains the preferred mode of revascularization, especially in patients with high lesion complexity and left ventricular dysfunction. Randomized studies are needed to understand if current-generation stents with the use of intracoronary imaging and improved medical therapy could match outcomes with surgical revascularization.
- Open Access
- 27 February 2023
- Published by Georg Thieme Verlag KG in AORTA
- Vol. 11 (01) , 047-049
Stanford Type A Aortic Dissection in A Patient with Primary Antiphospholipid Syndrome and Coronavirus Disease 2019
Acute aortic dissection is one of the most lethal diseases, affecting the lining of the aortic wall. We describe a case of Stanford Type A aortic dissection in a patient with underlying primary antiphospholipid syndrome (APS) complicated by coronavirus disease 2019 (COVID-19). APS is characterized by recurrent venous and/or arterial thrombosis, thrombocytopenia, and rarely vascular aneurysms. The hypercoagulable milieu attributable to APS and the prothrombotic state from COVID-19 posed a challenge in achieving optimal postoperative anticoagulation in our patient.
- 27 February 2023
- Published by Georg Thieme Verlag KG in AORTA
- Vol. 11 (01) , 047-049
Open AccessStanford Type A Aortic Dissection in A Patient with Primary Antiphospholipid Syndrome and Coronavirus Disease 2019
Acute aortic dissection is one of the most lethal diseases, affecting the lining of the aortic wall. We describe a case of Stanford Type A aortic dissection in a patient with underlying primary antiphospholipid syndrome (APS) complicated by coronavirus disease 2019 (COVID-19). APS is characterized by recurrent venous and/or arterial thrombosis, thrombocytopenia, and rarely vascular aneurysms. The hypercoagulable milieu attributable to APS and the prothrombotic state from COVID-19 posed a challenge in achieving optimal postoperative anticoagulation in our patient.
- 15 September 2022
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 46, 21-26
A Meta-Analysis of Traditional Radial Access and Distal Radial Access in Transradial Access for Percutaneous Coronary Procedures
- 15 September 2022
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 46, 21-26
A Meta-Analysis of Traditional Radial Access and Distal Radial Access in Transradial Access for Percutaneous Coronary Procedures
- 1 May 2022
- Published by Elsevier in The American Journal of Medicine
- Vol. 135 (5) , 626-633.e4
Targeted Hypothermia vs Targeted Normothermia in Survivors of Cardiac Arrest: A Systematic Review and Meta-Analysis of Randomized Trials
- 1 May 2022
- Published by Elsevier in The American Journal of Medicine
- Vol. 135 (5) , 626-633.e4
Targeted Hypothermia vs Targeted Normothermia in Survivors of Cardiac Arrest: A Systematic Review and Meta-Analysis of Randomized Trials